Magnetic resonance-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma

Jonna K. van Vulpen; Hidde Eijkelenkamp; Guus Grimbergen; Frank J. Wessels; Sasja F. Mulder; Gert J. Meijer; Martijn P.W. Intven

doi:10.1016/j.phro.2024.100683

Magnetic resonance-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma

Jonna K. van Vulpen^*
, Hidde Eijkelenkamp
, Guus Grimbergen
, Frank J. Wessels
, Sasja F. Mulder
, Gert J. Meijer
, Martijn P.W. Intven

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

4 Downloads (Pure)

Abstract

Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 % and 95 % (95 % CI 86–100 %), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 % (95 %CI 75–100 %) and 82 % (95 % CI 62–100 %), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.

Original language	English
Article number	100683
Number of pages	4
Journal	Physics and Imaging in Radiation Oncology
Volume	32
DOIs	https://doi.org/10.1016/j.phro.2024.100683
Publication status	Published - Oct 2024

Keywords

MR-guided SBRT
Oligometastases
Pancreatic metastases
Renal cell carcinoma

Access to Document

10.1016/j.phro.2024.100683Licence: CC BY-NC-ND

PIIS2405631624001532Final published version, 1.19 MBLicence: CC BY-NC-ND

Cite this

@article{647926ed17654da2b6d575450efaf916,

title = "Magnetic resonance-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma",

abstract = "Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 \% and 95 \% (95 \% CI 86–100 \%), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 \% (95 \%CI 75–100 \%) and 82 \% (95 \% CI 62–100 \%), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.",

keywords = "MR-guided SBRT, Oligometastases, Pancreatic metastases, Renal cell carcinoma",

author = "\{van Vulpen\}, \{Jonna K.\} and Hidde Eijkelenkamp and Guus Grimbergen and Wessels, \{Frank J.\} and Mulder, \{Sasja F.\} and Meijer, \{Gert J.\} and Intven, \{Martijn P.W.\}",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2024",

month = oct,

doi = "10.1016/j.phro.2024.100683",

language = "English",

volume = "32",

journal = "Physics and Imaging in Radiation Oncology",

issn = "2405-6316",

publisher = "Elsevier",

}

TY - JOUR

T1 - Magnetic resonance-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma

AU - van Vulpen, Jonna K.

AU - Eijkelenkamp, Hidde

AU - Grimbergen, Guus

AU - Wessels, Frank J.

AU - Mulder, Sasja F.

AU - Meijer, Gert J.

AU - Intven, Martijn P.W.

PY - 2024/10

Y1 - 2024/10

N2 - Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 % and 95 % (95 % CI 86–100 %), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 % (95 %CI 75–100 %) and 82 % (95 % CI 62–100 %), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.

AB - Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 % and 95 % (95 % CI 86–100 %), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 % (95 %CI 75–100 %) and 82 % (95 % CI 62–100 %), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.

KW - MR-guided SBRT

KW - Oligometastases

KW - Pancreatic metastases

KW - Renal cell carcinoma

UR - https://www.scopus.com/pages/publications/85210543267

U2 - 10.1016/j.phro.2024.100683

DO - 10.1016/j.phro.2024.100683

M3 - Article

AN - SCOPUS:85210543267

SN - 2405-6316

VL - 32

JO - Physics and Imaging in Radiation Oncology

JF - Physics and Imaging in Radiation Oncology

M1 - 100683

ER -

Magnetic resonance-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this